• 1
    Cogliano V,Baan R,Straif K,Grosse Y,Secretan B,El GF. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
  • 2
    Smith JS,Lindsay L,Hoots B,Keys J,Franceschi S,Winer R,Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 62132.
  • 3
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890907.
  • 4
    Kovacic MB,Castle PE,Herrero R,Schiffman M,Sherman ME,Wacholder S,Rodriguez AC,Hutchinson ML,Bratti MC,Hildesheim A,Morales J,Alfaro M, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66: 101129.
  • 5
    Kulasingam SL,Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 7819.
  • 6
    Wheeler CM,Franceschi S. EUROGIN 2007 roadmap–conclusion. Vaccine 2008; 26 ( Suppl 1): A28A31.
  • 7
    Sherman ME,Wang SS,Wheeler CM,Rich L,Gravitt PE,Tarone R,Schiffman M. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003; 12: 103844.
  • 8
    Carreon JD,Sherman ME,Guillen D,Solomon D,Herrero R,Jeronimo J,Wacholder S,Rodriguez AC,Morales J,Hutchinson M,Burk RD,Schiffman M. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007; 26: 4416.
  • 9
    Jeronimo J,Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol 2006; 195: 34953.
  • 10
    Wentzensen N,Schiffman M,Dunn ST,Zuna RE,Walker J,Allen RA,Zhang R,Sherman ME,Wacholder S,Jeronimo J,Gold MA,Wang SS. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int J Cancer 2009; 124: 9649.
  • 11
    Wang SS,Zuna RE,Wentzensen N,Dunn ST,Sherman ME,Gold MA,Schiffman M,Wacholder S,Allen RA,Block I,Downing K,Jeronimo J, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev 2009; 18: 11320.
  • 12
    Schiffman M,Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000; 44: 72642.
  • 13
    Dunn ST,Allen RA,Wang S,Walker J,Schiffman M. DNA extraction: an understudied and important aspect of HPV genotyping using PCR-based methods. J Virol Methods 2007; 143: 4554.
  • 14
    de Villiers EM,Fauquet C,Broker TR,Bernard HU,zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 1727.
  • 15
    Jeronimo J,Wentzensen N,Long R,Schiffman M,Dunn ST,Allen RA,Walker JL,Gold MA,Zuna RE,Sherman ME,Wacholder S,Wang SS. An evaluation of linear array HPV genotyping using an automatic optical imaging software. J Clin Microbiol 2008; 46: 275965.
  • 16
    Schiffman M,Herrero R,Desalle R,Hildesheim A,Wacholder S,Rodriguez AC,Bratti MC,Sherman ME,Morales J,Guillen D,Alfaro M,Hutchinson M, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 7684.
  • 17
    Bruzzi P,Green SB,Byar DP,Brinton LA,Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985; 122: 90414.
  • 18
    Wacholder S,Benichou J,Heineman EF,Hartge P,Hoover RN. Attributable risk: advantages of a broad definition of exposure. Am J Epidemiol 1994; 140: 3039.
  • 19
    Insinga RP,Liaw KL,Johnson LG,Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 161122.
  • 20
    Fuchs PG,Girardi F,Pfister H. Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of the cervix uteri. Int J Cancer 1988; 41: 415.
  • 21
    Lorincz AT,Temple GF,Kurman RJ,Jenson AB,Lancaster WD. Oncogenic association of specific human papillomavirus types with cervical neoplasia. J Natl Cancer Inst 1987; 79: 6717.
  • 22
    Lorincz AT,Reid R,Jenson AB,Greenberg MD,Lancaster W,Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79: 32837.
  • 23
    Franco EL,Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26 ( suppl 1): A16A23.
  • 24
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007; 111: 14553.
  • 25
    Castle PE,Schiffman M,Herrero R,Hildesheim A,Rodriguez AC,Bratti MC,Sherman ME,Wacholder S,Tarone R,Burk RD. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 180816.
  • 26
    Franceschi S,Herrero R,Clifford GM,Snijders PJ,Arslan A,Anh PT,Bosch FX,Ferreccio C,Hieu NT,Lazcano-Ponce E,Matos E,Molano M, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 267784.
  • 27
    Kjaer SK,Breugelmans G,Munk C,Junge J,Watson M,Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008; 123: 186470.
  • 28
    Lau S,Franco EL. Management of low-grade cervical lesions in young women. CMAJ 2005; 173: 7714.
  • 29
    Rodriguez AC,Schiffman M,Herrero R,Wacholder S,Hildesheim A,Castle PE,Solomon D,Burk R. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. JNatl Cancer Inst 2008; 100: 5137.
  • 30
    Sigurdsson K,Taddeo FJ,Benediktsdottir KR,Olafsdottir K,Sigvaldason H,Oddsson K,Rafnar T. HPV genotypes in CIN 2–3 lesions and cervical cancer: a population-based study. Int J Cancer 2007; 121: 26827.
  • 31
    Chaturvedi AK,Myers L,Hammons AF,Clark RA,Dunlap K,Kissinger PJ,Hagensee ME. Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev 2005; 14: 243945.
  • 32
    Franco EL,Villa LL,Sobrinho JP,Prado JM,Rousseau MC,Desy M,Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 141523.
  • 33
    Thomas KK,Hughes JP,Kuypers JM,Kiviat NB,Lee SK,Adam DE,Koutsky LA. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000; 182: 1097102.
  • 34
    Trottier H,Mahmud S,Costa MC,Sobrinho JP,Duarte-Franco E,Rohan TE,Ferenczy A,Villa LL,Franco EL. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 127480.
  • 35
    Goldie SJ,Kohli M,Grima D,Weinstein MC,Wright TC,Bosch FX,Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 60415.
  • 36
    Schiffman M,Khan MJ,Solomon D,Herrero R,Wacholder S,Hildesheim A,Rodriguez AC,Bratti MC,Wheeler CM,Burk RD. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005; 97: 14750.
  • 37
    Harper DM,Franco EL,Wheeler CM,Moscicki AB,Romanowski B,Roteli-Martins CM,Jenkins D,Schuind A,Costa Clemens SA,Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 124755.
  • 38
    Gravitt PE,Van Doorn LJ,Quint W,Schiffman M,Hildesheim A,Glass AG,Rush BB,Hellman J,Sherman ME,Burk RD,Wang SS. Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J Clin Microbiol 2007; 45: 324550.